» Articles » PMID: 35197453

Psilocin Acutely Alters Sleep-wake Architecture and Cortical Brain Activity in Laboratory Mice

Overview
Date 2022 Feb 24
PMID 35197453
Authors
Affiliations
Soon will be listed here.
Abstract

Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disorders, including depression. A prominent factor associated with psychiatric disorders is disturbed sleep, and the sleep-wake cycle is implicated in the homeostatic regulation of neuronal activity and synaptic plasticity. However, it remains largely unknown to what extent psychedelic agents directly affect sleep, in terms of both acute arousal and homeostatic sleep regulation. Here, chronic electrophysiological recordings were obtained in mice to track sleep-wake architecture and cortical activity after psilocin injection. Administration of psilocin led to delayed REM sleep onset and reduced NREM sleep maintenance for up to approximately 3 h after dosing, and the acute EEG response was associated primarily with an enhanced oscillation around 4 Hz. No long-term changes in sleep-wake quantity were found. When combined with sleep deprivation, psilocin did not alter the dynamics of homeostatic sleep rebound during the subsequent recovery period, as reflected in both sleep amount and EEG slow-wave activity. However, psilocin decreased the recovery rate of sleep slow-wave activity following sleep deprivation in the local field potentials of electrodes targeting the medial prefrontal and surrounding cortex. It is concluded that psilocin affects both global vigilance state control and local sleep homeostasis, an effect which may be relevant for its antidepressant efficacy.

Citing Articles

Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.

Weiss F, Magnesa A, Gambini M, Gurrieri R, Annuzzi E, Elefante C Brain Sci. 2025; 15(2).

PMID: 40002450 PMC: 11853016. DOI: 10.3390/brainsci15020117.


Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action.

Reid M, Kettner H, Blanken T, Weiss B, Carhartt-Harris R Curr Psychiatry Rep. 2024; 26(11):659-669.

PMID: 39532819 PMC: 11579049. DOI: 10.1007/s11920-024-01539-8.


Paradoxical pharmacological dissociations result from drugs that enhance delta oscillations but preserve consciousness.

Frohlich J, Mediano P, Bavato F, Gharabaghi A Commun Biol. 2023; 6(1):654.

PMID: 37340024 PMC: 10282051. DOI: 10.1038/s42003-023-04988-8.


The Putative Role of Neuroinflammation in the Interaction between Traumatic Brain Injuries, Sleep, Pain and Other Neuropsychiatric Outcomes: A State-of-the-Art Review.

Herrero Babiloni A, Baril A, Charlebois-Plante C, Jodoin M, Sanchez E, De Baets L J Clin Med. 2023; 12(5).

PMID: 36902580 PMC: 10002551. DOI: 10.3390/jcm12051793.


Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.

Traut J, Mengual J, Meijer E, McKillop L, Alfonsa H, Hoerder-Suabedissen A Elife. 2023; 12.

PMID: 36892930 PMC: 9998087. DOI: 10.7554/eLife.84740.


References
1.
Carhart-Harris R, Bolstridge M, Rucker J, Day C, Erritzoe D, Kaelen M . Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016; 3(7):619-27. DOI: 10.1016/S2215-0366(16)30065-7. View

2.
Carhart-Harris R, Goodwin G . The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. 2017; 42(11):2105-2113. PMC: 5603818. DOI: 10.1038/npp.2017.84. View

3.
Vollenweider F, Preller K . Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020; 21(11):611-624. DOI: 10.1038/s41583-020-0367-2. View

4.
Vollenweider F, Vollenweider-Scherpenhuyzen M, Babler A, Vogel H, Hell D . Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1999; 9(17):3897-902. DOI: 10.1097/00001756-199812010-00024. View

5.
Halberstadt A . Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res. 2014; 277:99-120. PMC: 4642895. DOI: 10.1016/j.bbr.2014.07.016. View